205 related articles for article (PubMed ID: 11309459)
1. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system.
Gläsker S; Bender BU; Apel TW; van Velthoven V; Mulligan LM; Zentner J; Neumann HP
J Neurol Neurosurg Psychiatry; 2001 May; 70(5):644-8. PubMed ID: 11309459
[TBL] [Abstract][Full Text] [Related]
2. Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.
Shankar GM; Taylor-Weiner A; Lelic N; Jones RT; Kim JC; Francis JM; Abedalthagafi M; Borges LF; Coumans JV; Curry WT; Nahed BV; Shin JH; Paek SH; Park SH; Stewart C; Lawrence MS; Cibulskis K; Thorner AR; Van Hummelen P; Stemmer-Rachamimov AO; Batchelor TT; Carter SL; Hoang MP; Santagata S; Louis DN; Barker FG; Meyerson M; Getz G; Brastianos PK; Cahill DP
Acta Neuropathol Commun; 2014 Dec; 2():167. PubMed ID: 25589003
[TBL] [Abstract][Full Text] [Related]
3. Central nervous system capillary haemangioblastoma: the pathologist's viewpoint.
Hussein MR
Int J Exp Pathol; 2007 Oct; 88(5):311-24. PubMed ID: 17877533
[TBL] [Abstract][Full Text] [Related]
4. A germline 1;3 translocation disrupting the
Ricketts CJ; Vocke CD; Lang M; Chen X; Zhao Y; Tran B; Tandon M; Schmidt LS; Ball MW; Linehan WM
J Med Genet; 2022 Jan; 59(1):18-22. PubMed ID: 33067352
[TBL] [Abstract][Full Text] [Related]
5. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
[TBL] [Abstract][Full Text] [Related]
6. Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease.
Albiñana V; Escribano RMJ; Soler I; Padial LR; Recio-Poveda L; Villar Gómez de Las Heras K; Botella LM
Orphanet J Rare Dis; 2017 Jun; 12(1):122. PubMed ID: 28662711
[TBL] [Abstract][Full Text] [Related]
7. Von Hippel-Lindau disease (VHL): a need for a murine model with retinal hemangioblastoma.
Park S; Chan CC
Histol Histopathol; 2012 Aug; 27(8):975-84. PubMed ID: 22763871
[TBL] [Abstract][Full Text] [Related]
8. A mutation at IVS1 + 5 of the von Hippel-Lindau gene resulting in intron retention in transcripts is not pathogenic in a patient with a tongue cancer?: case report.
Asakawa T; Esumi M; Endo S; Kida A; Ikeda M
BMC Med Genet; 2012 Mar; 13():23. PubMed ID: 22462637
[TBL] [Abstract][Full Text] [Related]
9. Mutation in Chek2 triggers von Hippel-Lindau hemangioblastoma growth.
Cabrera-Montes J; Aguirre DT; Viñas-López J; Lorente-Herraiz L; Recio-Poveda L; Albiñana V; Pérez-Pérez J; Botella LM; Cuesta AM
Acta Neurochir (Wien); 2023 Dec; 165(12):4241-4251. PubMed ID: 37843608
[TBL] [Abstract][Full Text] [Related]
10. Neurological applications of belzutifan in von Hippel-Lindau disease.
Zhang Y; Nguyen CC; Zhang NT; Fink NS; John JD; Venkatesh OG; Roe JD; Hoffman SC; Lesniak MS; Wolinsky JP; Horbinski C; Szymaniak BM; Buerki RA; Sosman JA; Shenoy NK; Lukas RV
Neuro Oncol; 2023 May; 25(5):827-838. PubMed ID: 36215167
[TBL] [Abstract][Full Text] [Related]
11. A novel mutation in the von hippel-lindau tumor suppressor gene identified in a patient presenting with gestational diabetes mellitus.
Ku YH; Ahn CH; Jung CH; Lee JE; Kim LK; Kwak SH; Jung HS; Park KS; Cho YM
Endocrinol Metab (Seoul); 2013 Dec; 28(4):320-5. PubMed ID: 24396697
[TBL] [Abstract][Full Text] [Related]
12. Proteostasis Modulation in Germline Missense von Hippel Lindau Disease.
Chittiboina P; Mandal D; Bugarini A; Asuzu DT; Mullaney D; Mastorakos P; Stoica S; Alvarez R; Scott G; Maric D; Elkahloun A; Zhuang Z; Chew EY; Yang C; Linehan M; Lonser RR
Clin Cancer Res; 2023 Jun; 29(12):2199-2209. PubMed ID: 37018064
[TBL] [Abstract][Full Text] [Related]
13. Von hippel-lindau disease.
Hes FJ; Höppener JW; Luijt RB; Lips CJ
Hered Cancer Clin Pract; 2005 Nov; 3(4):171-8. PubMed ID: 20223044
[TBL] [Abstract][Full Text] [Related]
14. Von Hippel-Lindau Disease.
Findeis-Hosey JJ; McMahon KQ; Findeis SK
J Pediatr Genet; 2016 Jun; 5(2):116-23. PubMed ID: 27617152
[TBL] [Abstract][Full Text] [Related]
15. First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma.
Dhawan A; Peereboom DM; Stevens GH
CNS Oncol; 2022 Jul; 11(3):CNS91. PubMed ID: 35819008
[TBL] [Abstract][Full Text] [Related]
16. VHL: Trends and Insight into a Multi-Modality, Interdisciplinary Approach for Management of Central Nervous System Hemangioblastoma.
Matloob SA; Paraskevopoulos D; O'Toole SM; Drake W; Plowman N; Foroglou N
Acta Neurochir Suppl; 2023; 135():81-88. PubMed ID: 38153453
[TBL] [Abstract][Full Text] [Related]
17. Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease.
Knoblauch AL; Blaß BI; Steiert C; Neidert N; Puzik A; Neumann-Haefelin E; Ganner A; Kotsis F; Schäfer T; Neumann HPH; Elsheikh S; Beck J; Klingler JH
J Neurooncol; 2024 Apr; ():. PubMed ID: 38647646
[TBL] [Abstract][Full Text] [Related]
18. The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?
Cinque A; Minnei R; Floris M; Trevisani F
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358771
[TBL] [Abstract][Full Text] [Related]
19. A Case of Von Hippel-Lindau Disease With Recurrence of Paraganglioma and No Other Associated Symptoms: The Importance of Genetic Testing and Establishing Follow-Up Policies.
Okada N; Shioya A; Togi S; Ura H; Niida Y
Cureus; 2023 Dec; 15(12):e50484. PubMed ID: 38222164
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
